The Pancreatic Cancer Action Network (PSC) of the United States informs their members about Immunovia's blood test IMMray PanCan-d
It was announced today that the largest u.s. group for pancreatic cancer (PanCAN) established its own laboratory and approved its drug tests in the United States.
PanCan - Pancan. She underlines her support. IMMray - PanCan-d is the first-ever blood test for pancreatic cancer. It is available to people at high risk of the disease due to family history or genetic alterations. PanCAN recommends the test for the patient, and the doctor requests the tests from Immunovia, Inc. Interested individuals can contact PanCan Patient Services, which provides free information and answers questions about the IMMrayTM Pancan-
"Pancreatic cancer is a serious disease. The general population doesn't have an early detection test and there's very few treatment options, so it'll be exciting to see progress progress. The Immunovia IMMrayTM PanCan-d test is a significant step for some patients to be diagnosed earlier, have more treatment options and live longer, said Julie Fleshman, JD, MBA, President and CEO
"It's of great value that PanCAN helps raise awareness about Immunovia, Inc.' s blood test IMMrayTM PanCan-d in the US. PanCAN is reaching a very large audience and speaks directly to persons in the familial/hereditary risk group that need to be given the opportunity to get tested", said Patrik Dahlen, Immunovia's CEO.
IMMrayTM PanCan-d was launched in August by Immunovia Inc. in the US and is currently available in all states, except New York, California, Maryland, Pennsylvania and Rhode Island.
For more information, please contact: Patrik Dahlen, CEO ImmunoviaEmail: [email protected] Tel: +46 73 376 76 64.
About Immunovia Immunovia AB is a diagnostic company developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on the proprietary IMMray platform. The tests are fabricated from antibodies biomarkers to So, forming a unique "disease biomarker signature".
The company was founded in 2007, based on cancer studies and the ground-breaking research conducted in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center in Sweden.
The first product, IMMrayTM PanCan-d, is being tested in the world's largest clinical trials for high-risk groups in pancreatic cancer, a clinical evaluation of the first of many of its major products, PanFAM-1, PanSYM-one and PanDIA-1. .
In 2017, Immunovia Inc. was established in Marlborough, Massachusetts, USA. The IMMrayTM PanCan-d test, the first blood-based test in the market to detect pancreatic cancer, is available exclusively through Immunovia, Inc. www.immunoviainc.com www-imunia.info. . The European launch plan will be communicated during the second half of 2021.
The shares of Immunovia (IMMNOV) are listed in the Nasdaq Stockholm. For more information, please visit the website. www.immunovia.com www wwwsimuniaas.cn. .
SOURCE Immunovia AB SURCE AUROMICS SOS.